Japan Q2 GDP 1% surprise leads Nikkei to new high; Dow rises as Buffett piles into embattled Unitedhealth Group with a murdered CEO - Fri 15 Aug 2025

Nikkei 225 Summary
Japan Q2 GDP 1% surprise leads Nikkei to new high; Dow rises as Buffett piles into embattled Unitedhealth Group with a murdered CEO - Fri 15 Aug 2025

MUFG (+6.01%) leads banks higher as the Nikkei hits a new high again after Japan's Q2 GDP rises by a surprising 1.0%, showing Bushido resilience amid punishing Trump tariffs.

Meanwhile, Dow rises after Warren Buffett’s Berkshire Hathaway buys 5 million shares ($1.57 billion) in embattled Unitedhealth Group in June 2025. The health care provider reported a disappointing Q2 and its CEO, Brian Thompson, was shot and killed on December 4, 2024, outside the New York Hilton Midtown. 

Nikkei225  43,378.31 (+729.05 +1.71%) 177 up 46 down 2 flat

JGB 10YR   1.548% (+0.028)            

USD/JPY    147.87 (+0.49 +0.33%)


 

Comments

Post a Comment

Popular posts from this blog

IHI Launches New Bench-Scale Sustainable Aviation Fuel (SAF) Test Rig in Singapore with A*STAR ISCE²

Image
IHI and IHI ASIA PACIFIC PTE. LTD. (“IHI”), in collaboration with the A*STAR Institute of Sustainability for Chemicals, Energy and Environment (“A*STAR ISCE 2 ”) (*1) in Singapore, held an opening ceremony to mark the completion of a Sustainable Aviation Fuel (SAF) (*2) production test rig for CO 2 direct-conversion to liquid hydrocarbons, with a capacity of 5 kg per day. The technology streamlines the process by enabling a single step carbon dioxide direct-conversion to liquid hydrocarbons. This approach simplifies the production process, thus enhancing energy efficiency and reducing operational complexity.    The event was attended by over 100 guests, including government officials from various countries and the companies and organizations involved in the SAF value chain. IHI showcased the SAF production technology currently under development and its future ambition toward commercialization. The International Civil Aviation Organization (ICAO) has set a long-t...
Read more

Astroscale & BAE Systems Designing In-Orbit Satellite Refurbishment & Upgrade services

Image
Astroscale is collaborating with BAE Systems to advance the transition to a circular space economy and support the UK’s ambitions for In-Orbit Servicing, Assembly and Manufacturing – the fastest growing segment of the space industry.   The organisations recently completed a six-month feasibility study to develop an In-orbit Refurbishment and Upgrading Service, building on Astroscale’s existing servicer technology to enable the upgrade of a BAE Systems satellite.   The consortium’s long-term objective is an In-Orbit Demonstration mission by 2030.    Harwell, Oxford, UK, Mar. 05 , 2025 – Astroscale Limited (“Astroscale UK”), the UK subsidiary of Astroscale Holdings Inc. (“Astroscale”), the market leader in satellite servicing and long-term orbital sustainability, has today announced the successful completion of a study aimed at developing capabilities to refurbish and upgrade satellites for commercial use.    As part of the European Space Agency’s...
Read more

Daiichi Sankyo & AstraZeneca start Phase 3 Trial of DESTINY-Gastric05 for Gastric Cancer treatment

Image
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer Tokyo and Basking Ridge, NJ – (March 31, 2025) – The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with a fluoropyrimidine chemotherapy (5-FU or capecitabine) and Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) versus trastuzumab in combination with platinum-based chemotherapy (cisplatin plus 5-FU or oxaliplatin plus capecitabine) and pembrolizumab in previously untreated patients with unresectable, locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction (GEJ) cancer with PD-L1 CPS ≥1. An exploratory cohort of patients with PD-L1 CPS <1 will be randomized to either ENHERTU plus fluoropyrimidine or trastuzumab plus platinum-based chemotherapy. ENHERTU is a specifically engineered...
Read more